$TTNP
TITAN PHARMACEUTICALS INC Stock $ttnp

$ttnp Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000182912624002110 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$0.00	$184.0K
YoY Change		-100.0%	-66.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.063M	$1.444M	$5.548M
YoY Change	-13.86%	12.02%	-8.05%
% of Gross Profit
Research & Development		$487.0K	$1.913M
YoY Change		-66.25%	-59.79%
% of Gross Profit
Depreciation & Amortization	$2.000K	$3.000K	$112.0K
YoY Change	-95.35%	-93.33%	-42.86%
% of Gross Profit
Operating Expenses	$1.063M	$1.931M	$7.461M
YoY Change	89.48%	-29.32%	-30.87%
Operating Profit	-$1.063M		-$7.277M
YoY Change	-37.36%		-28.9%
Interest Expense	$1.000K	-$13.00K	$5.000K
YoY Change	-95.45%	-148.15%	-90.57%
% of Operating Profit
Other Income/Expense, Net	$3.000K	-$49.00K	$1.708M
YoY Change	-86.36%	-372.22%	5789.66%
Pretax Income	-$1.060M	-$1.970M	-$5.569M
YoY Change	-36.72%	-23.23%	-45.43%
Income Tax			$1.000K
% Of Pretax Income
Net Earnings	-$1.060M	-$1.970M	-$5.569M
YoY Change	-36.72%	-23.23%	-45.43%
Net Earnings / Revenue			-3026.63%
Basic Earnings Per Share	-$1.24		-$7.41
Diluted Earnings Per Share	-$1.24	-$2.61	-$7.41
COMMON SHARES
Basic Shares Outstanding	914.2K shares	15.02M shares	752.0K shares
Diluted Shares Outstanding	853.0K shares		752.0K shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.159M	$6.760M	$6.760M
YoY Change	442.17%	130.17%	130.17%
Cash & Equivalents	$6.159M	$6.760M	$6.760M
Short-Term Investments
Other Short-Term Assets	$318.0K	$212.0K	$212.0K
YoY Change	-40.56%	-59.54%	-59.54%
Inventory		$0.00	$0.00
Prepaid Expenses
Receivables	$134.0K	$46.00K	$46.00K
Other Receivables	$0.00	$1.000M	$1.000M
Total Short-Term Assets	$6.611M	$8.018M	$8.018M
YoY Change	270.36%	122.54%	122.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.000K	$5.000K	$68.00K
YoY Change	-98.34%	-97.77%	-83.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$35.00K	$68.00K	$68.00K
YoY Change	-90.86%	-85.05%	-85.05%
TOTAL ASSETS
Total Short-Term Assets	$6.611M	$8.018M	$8.018M
Total Long-Term Assets	$35.00K	$68.00K	$68.00K
Total Assets	$6.646M	$8.086M	$8.086M
YoY Change	206.55%	99.26%	99.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$371.0K	$348.0K	$348.0K
YoY Change	-34.57%	-49.93%	-49.93%
Accrued Expenses	$188.0K	$584.0K	$584.0K
YoY Change	-88.21%	-63.73%	-63.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$500.0K	$500.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$559.0K	$1.444M	$1.444M
YoY Change	-77.16%	-45.1%	-45.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$559.0K	$1.444M	$1.444M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$559.0K	$1.444M	$1.444M
YoY Change	-77.46%	-46.42%	-46.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$392.9M	-$391.8M
YoY Change	1.28%	1.44%
Common Stock	$1.000K	$1.000K
YoY Change	-93.33%	-93.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.087M	$6.642M	$6.642M
YoY Change
Total Liabilities & Shareholders Equity	$6.646M	$8.086M	$8.086M
YoY Change	206.55%	99.26%	99.26%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.060M	-$1.970M	-$5.569M
YoY Change	-36.72%	-23.23%	-45.43%
Depreciation, Depletion And Amortization	$2.000K	$3.000K	$112.0K
YoY Change	-95.35%	-93.33%	-42.86%
Cash From Operating Activities	-$613.0K	-$2.246M	-$7.092M
YoY Change	-67.72%	42.24%	-13.33%
INVESTING ACTIVITIES
Capital Expenditures		$2.000K	$2.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$506.0K	$734.0K
YoY Change
Cash From Investing Activities		$504.0K	$732.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		406.0K	$10.00M
YoY Change			100.64%
NET CHANGE
Cash From Operating Activities	-$613.0K	-2.246M	-$7.092M
Cash From Investing Activities		504.0K	$732.0K
Cash From Financing Activities		406.0K	$10.00M
Net Change In Cash	-$613.0K	-1.336M	$3.640M
YoY Change	-67.72%	-15.39%	-213.79%
FREE CASH FLOW
Cash From Operating Activities	-$613.0K	-$2.246M	-$7.092M
Capital Expenditures		$2.000K	$2.000K
Free Cash Flow		-$2.248M	-$7.094M
YoY Change		42.37%	-13.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet		usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2022Q4	ttnp	Note Payable To Related Party NotePayableToRelatedParty		usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets		usd
CY2023	ttnp	Release Of Unrestricted Stock ReleaseOfUnrestrictedStock		usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets		usd
CY2023	ttnp	Share Based Payment Arrangement Milestone Payment ShareBasedPaymentArrangementMilestonePayment		usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2022	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	ttnp	Proceeds From Equity Offerings ProceedsFromEquityOfferings		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022	us-gaap	Proceeds From Subordinated Short Term Debt ProceedsFromSubordinatedShortTermDebt		usd
CY2022	us-gaap	Repayments Of Subordinated Short Term Debt RepaymentsOfSubordinatedShortTermDebt		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	ttnp	Inventory Transferred With Sale Of Assets InventoryTransferredWithSaleOfAssets		usd
CY2022	ttnp	Property And Equipment Net Transferred With Sale Of Assets PropertyAndEquipmentNetTransferredWithSaleOfAssets		usd
CY2022	ttnp	Notes Receivable Received In Connection With Sale Of Assets NotesReceivableReceivedInConnectionWithSaleOfAssets		usd
CY2022	ttnp	Other Accrued Liabilities Transferred With Sale Of Assets OtherAccruedLiabilitiesTransferredWithSaleOfAssets		usd
CY2022	ttnp	Other Accrued Liabilities Related To Stockbased Compensation OtherAccruedLiabilitiesRelatedToStockbasedCompensation		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	ttnp	Share Based Compensation Arrangements By Share Based Payment Award Options Released In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReleasedInPeriodWeightedAverageExercisePrice
CY2023Q4	ttnp	Sharebased Compensation Arrangement By Sharebased Payment Award Options Released Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsReleasedIntrinsicValue1		usd
CY2023Q4	ttnp	Sharebased Compensation Arrangement By Sharebased Payment Award Options Cancelled And Expired Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledAndExpiredIntrinsicValue1		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments		usd
CY2023Q3	us-gaap	Inventory Net InventoryNet		usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
	ttnp	Share Based Payment Arrangement Milestone Payment ShareBasedPaymentArrangementMilestonePayment		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	East Brunswick, New Jersey
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6760000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2937000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	13000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	196000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	46000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36000	usd
CY2023Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	1000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	-0	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	106000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	199000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	314000	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	14000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	8018000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3603000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	224000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	183000	usd
CY2023Q4	us-gaap	Assets Assets	8086000	usd
CY2022Q4	us-gaap	Assets Assets	4058000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	348000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	695000	usd
CY2023Q4	ttnp	Note Payable To Related Party NotePayableToRelatedParty	500000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	519000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1488000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	122000	usd
CY2023Q4	ttnp	Deferred Grant Revenue DeferredGrantRevenue	12000	usd
CY2022Q4	ttnp	Deferred Grant Revenue DeferredGrantRevenue	196000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	129000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1444000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2630000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	65000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2695000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	950000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	950000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	781503	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	781503	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	750815	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	750815	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	387623000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-386261000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1363000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4058000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	184000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	557000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	557000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4758000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6034000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	10792000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10235000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	53000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	24000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	29000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10206000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.41
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.41
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-15.19
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-15.19
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	752000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	752000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	672000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	672000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5138000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10206000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5030000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	450000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	947000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1363000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5569000	usd
CY2023	ttnp	Issuance Of Preferred Stock Net IssuanceOfPreferredStockNet	9500000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	25000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1323000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6642000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-5569000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-10206000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	112000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	196000	usd
CY2023	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	1755000	usd
CY2022	ttnp	Share Based Payment Arrangement Milestone Payment ShareBasedPaymentArrangementMilestonePayment	50000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1013000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	947000	usd
CY2023	ttnp	Amortization Of Restricted Stock AmortizationOfRestrictedStock	25000	usd
CY2022	ttnp	Amortization Of Restricted Stock AmortizationOfRestrictedStock	450000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	2000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-76000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-187000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-177000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-164000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-476000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-751000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-423000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	801000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-184000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-99000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7092000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8183000	usd
CY2023	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	734000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	732000	usd
CY2022	ttnp	Proceeds From Equity Offerings ProceedsFromEquityOfferings	4980000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9500000	usd
CY2023	us-gaap	Proceeds From Subordinated Short Term Debt ProceedsFromSubordinatedShortTermDebt	750000	usd
CY2023	us-gaap	Repayments Of Subordinated Short Term Debt RepaymentsOfSubordinatedShortTermDebt	250000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4984000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3640000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3199000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3133000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6332000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6773000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3133000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	21000	usd
CY2023	ttnp	Inventory Transferred With Sale Of Assets InventoryTransferredWithSaleOfAssets	106000	usd
CY2023	ttnp	Property And Equipment Net Transferred With Sale Of Assets PropertyAndEquipmentNetTransferredWithSaleOfAssets	109000	usd
CY2023	ttnp	Notes Receivable Received In Connection With Sale Of Assets NotesReceivableReceivedInConnectionWithSaleOfAssets	1000000	usd
CY2023	ttnp	Other Accrued Liabilities Transferred With Sale Of Assets OtherAccruedLiabilitiesTransferredWithSaleOfAssets	236000	usd
CY2023	ttnp	Other Accrued Liabilities Related To Stockbased Compensation OtherAccruedLiabilitiesRelatedToStockbasedCompensation	310000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6760000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2937000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	13000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	196000	usd
CY2023Q4	ttnp	Cash And Cash Equivalents And Restricted Cash Equivalents CashAndCashEquivalentsAndRestrictedCashEquivalents	6773000	usd
CY2022Q4	ttnp	Cash And Cash Equivalents And Restricted Cash Equivalents CashAndCashEquivalentsAndRestrictedCashEquivalents	3133000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6800000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_z520yFiurfS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><b><i><span id="xdx_867_zGrxKvFzk8Cg">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	60000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	46000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	106000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	106000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	2600000	usd
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	112000	usd
CY2022	ttnp	Contract With Customer Asset Additions ContractWithCustomerAssetAdditions	557000	usd
CY2022	ttnp	Contract With Customer Asset Deductions ContractWithCustomerAssetDeductions	-633000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	36000	usd
CY2023	ttnp	Contract With Customer Asset Additions ContractWithCustomerAssetAdditions	184000	usd
CY2023	ttnp	Contract With Customer Asset Deductions ContractWithCustomerAssetDeductions	-174000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	46000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	497000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	331000	shares
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	66000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	66000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	65000	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	781503	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	750815	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	950000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	711000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1817000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	706000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1593000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	224000	usd
CY2023	ttnp	Reimbursement Fees ReimbursementFees	50000000	usd
CY2023	ttnp	Operating Leases Rent Expenses OperatingLeasesRentExpenses	100000	usd
CY2022	ttnp	Operating Leases Rent Expenses OperatingLeasesRentExpenses	100000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Share Price SharePrice	10.00
CY2023	ttnp	Purchase Price PurchasePrice	9500000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2500	shares
CY2023	ttnp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod	-2500	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	484000	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	577000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	46000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	164.95
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M2D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	79000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.23
CY2023Q4	ttnp	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedIntrinsicValue1	283000	usd
CY2023	ttnp	Share Based Compensation Arrangement By Share Based Payment Award Options Released In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReleasedInPeriod	-28000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	4000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	479.56
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	93000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	73.46
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P8Y4M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	93000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	73.46
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y4M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.041	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M10D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M3D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.0110	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.0116	pure
CY2023	ttnp	Estimated Forfeiture Rates For Options Granted To Management EstimatedForfeitureRatesForOptionsGrantedToManagement	0.07	pure
CY2022	ttnp	Estimated Forfeiture Rates For Options Granted To Management EstimatedForfeitureRatesForOptionsGrantedToManagement	0.06	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.66
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	19.00
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1013000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	947000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	53225000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	57895000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9841000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10521000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1980000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1968000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	65046000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70384000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	19000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	46000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	46000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	65027000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70338000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5300000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7500000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1084000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2144000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	11000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-488000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5310000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7545000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	218000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	627000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	233000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-3489000	usd
CY2023	ttnp	Tax Attributes Expirations TaxAttributesExpirations	-6314000	usd
CY2022	ttnp	Tax Attributes Expirations TaxAttributesExpirations	-6216000	usd
CY2023	ttnp	Income Tax Reconciliation Impact Of Internal Revenue Code IncomeTaxReconciliationImpactOfInternalRevenueCode	83000	usd
CY2022	ttnp	Income Tax Reconciliation Impact Of Internal Revenue Code IncomeTaxReconciliationImpactOfInternalRevenueCode	-159000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	ttnp	Proceeds From Promissory Note ProceedsFromPromissoryNote	109000000	usd
CY2022	ttnp	Proceeds From Promissory Note ProceedsFromPromissoryNote	75000000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8096000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	13000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26000	usd
CY2023Q3	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	1500000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	244000	usd
CY2023Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	20000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	9899000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	94000	usd
CY2023Q3	us-gaap	Assets Assets	9999000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	407000	usd
CY2023Q3	ttnp	Note Payable To Related Party NotePayableToRelatedParty	500000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	790000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	97000	usd
CY2023Q3	ttnp	Deferred Grant Revenue DeferredGrantRevenue	12000	usd
CY2023Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	60000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1866000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	1866000	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	398383000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-390266000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	8133000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9999000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	424000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2047000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	2471000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2467000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11000	usd
CY2023Q3	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	1732000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1723000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-744000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15016000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15016000	shares
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	184000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1426000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4510000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	5936000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5752000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	18000	usd
	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	1732000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1747000	usd
	us-gaap	Profit Loss ProfitLoss	-4005000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15016000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15016000	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4005000	usd
	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	1732000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	109000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	965000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-122000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-374000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-184000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-152000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5252000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	228000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	228000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9500000	usd
	us-gaap	Proceeds From Subordinated Short Term Debt ProceedsFromSubordinatedShortTermDebt	750000	usd
	us-gaap	Repayments Of Subordinated Short Term Debt RepaymentsOfSubordinatedShortTermDebt	250000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	4976000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3133000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8109000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4000	usd
	ttnp	Inventory Transferred With Sale Of Assets InventoryTransferredWithSaleOfAssets	106000	usd
	ttnp	Property And Equipment Net Transferred With Sale Of Assets PropertyAndEquipmentNetTransferredWithSaleOfAssets	109000	usd
	ttnp	Notes Receivable Received In Connection With Sale Of Assets NotesReceivableReceivedInConnectionWithSaleOfAssets	1500000	usd
	ttnp	Accounts Payable Related To Sale Of Assets AccountsPayableRelatedToSaleOfAssets	17000	usd
	ttnp	Other Accrued Liabilities Transferred With Sale Of Assets OtherAccruedLiabilitiesTransferredWithSaleOfAssets	236000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8096000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	13000	usd
CY2023Q3	ttnp	Cash Cash Equivalents And Restricted Cash Shown In Condensed Statements Of Cash Flows CashCashEquivalentsAndRestrictedCashShownInCondensedStatementsOfCashFlows	8109000	usd

Files In Submission

Name	View Source	Status
0001829126-24-002110-index-headers.html	Edgar Link	pending
0001829126-24-002110-index.html	Edgar Link	pending
0001829126-24-002110.txt	Edgar Link	pending
0001829126-24-002110-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
titanpharma_10k.htm	Edgar Link	pending
titanpharma_ex23-1.htm	Edgar Link	pending
titanpharma_ex31-1.htm	Edgar Link	pending
titanpharma_ex32-1.htm	Edgar Link	pending
titanpharma_ex97i.htm	Edgar Link	pending
ttnp-20231231.xsd	Edgar Link	pending
ttnp-20231231_def.xml	Edgar Link	unprocessable
ttnp-20231231_lab.xml	Edgar Link	unprocessable
ttnp-20231231_pre.xml	Edgar Link	unprocessable
titanpharma_10k_htm.xml	Edgar Link	completed
ttnp-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TTNP
TITAN PHARMACEUTICALS INC Stock $ttnp

2024 Q1 Form 10-K Financial Statement

#000182912624002110 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTNP TITAN PHARMACEUTICALS INC Stock $ttnp

2024 Q1 Form 10-K Financial Statement

#000182912624002110 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TTNP
TITAN PHARMACEUTICALS INC Stock $ttnp